MAC ClauseThe Escape Hatch That Rarely Opens
A Material Adverse Change clause lets a buyer exit a signed SPA if something fundamental changes — but courts set the bar extraordinarily high. Two contrasting cases show exactly when it fails and when it succeeds.
What Is a MAC Clause?
A MAC (Material Adverse Change) clause — also called a MAE (Material Adverse Effect) clause — is a contractual provision that allows the buyer to terminate a signed SPA if a materially adverse change occurs in the target company or its industry between signing and closing. It is designed as buyer insurance, but in practice courts almost never accept a MAC claim as valid.
💡 Analogy
Imagine you put a deposit on a house — then before you hand over the full payment, the house burns down. A MAC clause protects you in that scenario: you shouldn't have to buy a fundamentally different asset at the originally agreed price. But "the market went down" or "I changed my mind" doesn't qualify. The fire has to be real, structural, and undeniable.
The Bar Courts Set — Extremely High
Delaware's Court of Chancery — the authoritative venue for M&A disputes — applies a rigorous standard. All of the following conditions must effectively be met for a MAC claim to succeed.
A stock price drop, a weak quarter, or a temporary business slowdown is not a MAC. The change must durably and structurally impair the company's long-term value.
Pandemics, interest rate spikes, recessions, wars — macro events affecting the whole industry are usually carved out of the MAC definition by SPA carve-outs. This is standard drafting practice.
"The price looks too high now" is not a MAC. The business model, core assets, or revenue-generating capacity must be structurally destroyed.
If the risk was publicly known or disclosed before the SPA was signed, the buyer cannot invoke it as a new MAC afterward. It must be a genuinely new development.
Negotiation Dynamics
The scope of the MAC definition is itself a major negotiation battleground.
Buyer's Strategy
Define MAC as broadly as possible. Keep the carve-out list short and narrow. Maximize the number of scenarios in which the buyer can walk away.
Seller's Strategy
Define MAC as narrowly as possible. Carve out industry-wide risks, economic conditions, interest rate changes, war, and any other systemic risks. Leave the buyer no escape route.
In practice, the most contested point is whether a carve-out applies when the target is "disproportionately affected" compared to peers — sellers want to remove this exception; buyers want to keep it.
Cases — MAC Accepted vs. Rejected
These two cases, side by side, make the court's standard unmistakably clear.
Musk × Twitter — "Bot Accounts = MAC" Rejected
$44B deal / 2022
💡 Context
The textbook case for what courts won't accept as a MAC: "the price looks too rich now."
In July 2022, Musk declared that Twitter's alleged misrepresentation of its bot account numbers constituted a MAC, and attempted to terminate the $44B deal. Twitter's stock had fallen well below the agreed price of $54.20, making the deal look expensive.
Twitter fired back immediately: the bot account issue was publicly known before the SPA was signed. It was not a new MAC — it was a pre-existing, disclosed risk. Delaware's Court of Chancery signaled that the MAC argument was unlikely to succeed.
Rather than face a near-certain Specific Performance order compelling him to close at $54.20 anyway, Musk agreed to complete the acquisition at the original price just before trial began. The MAC claim effectively failed.
🔑 Key Lesson
Courts almost never accept a MAC claim. Pre-existing risks, price remorse, and temporary deterioration don't qualify. Invoking MAC as a backdoor exit from an overpriced deal almost always backfires.
Akorn × Fresenius — A MAC That Actually Held Up
$4.3B deal / 2017–2018
💡 Context
Not a falling price — a house with structural damage that wasn't visible until after the contract was signed.
In 2017, Germany's Fresenius agreed to acquire U.S. generic drug maker Akorn for $4.3B. After signing, post-signing diligence uncovered something alarming:
Akorn had submitted fabricated data to the FDA, and its regulatory compliance systems had essentially collapsed. Fresenius reported this to the FDA directly. An FDA investigation confirmed the violations.
In 2018, Delaware's Court of Chancery ruled that this constituted a genuine MAC — not a financial downturn, but a structural destruction of the company's regulatory standing and core business value. This is one of the extremely rare instances in Delaware history where a MAC claim was formally upheld.
🔑 Key Lesson
For MAC to succeed, the company must be fundamentally different from what was contracted for — not just cheaper or less appealing. Akorn's FDA data fraud met that bar because it structurally destroyed the company's value as a regulated pharmaceutical business. Cases like this are extremely rare.
Side-by-Side Comparison
| Musk × Twitter | Akorn × Fresenius | |
|---|---|---|
| MAC claim basis | Bot account misrepresentation | FDA data fraud & compliance collapse |
| Court outcome | MAC effectively rejected | MAC formally upheld (historic) |
| Result | Buyer forced to close at original price | Termination permitted |
| Key distinction | Pre-existing, known risk before signing | Post-signing discovery of structural fraud |
🔑 Key Insight
The MAC clause looks like buyer insurance, but courts apply an extremely high bar before accepting it. Narrowing the MAC definition is the seller's strategy; broadening it is the buyer's. But even with a wide MAC clause, if the SPA includes a Specific Performance provision, a court can compel the buyer to close regardless — making MAC just one layer of a more complex picture.